1.71
-0.08
(-4.47%)
Jun 19 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 1.70 - 1.80 |
| 52 week | 1.08 - 4.95 |
| Open | 1.77 |
| Vol / Avg. | 477,614.00/795,923.00 |
| Mkt cap | 90.88M |
| P/E | - |
| Div/yield | - |
| EPS | -0.75 |
| Shares | 53.15M |
| Beta | 2.54 |
| Inst. own | 32% |
Events
Aug 6, 2013
Q2 2013 BioCryst Pharmaceuticals Earnings Release (Tentative)
Jun 6, 2013
BioCryst Pharmaceuticals at Jefferies Global Healthcare Conference
May 31, 2013
BioCryst Pharmaceuticals Annual Shareholder Meeting
May 16, 2013
BioCryst Pharmaceuticals at Bank of America Merrill Lynch Health Care Conference
May 7, 2013
Q1 2013 BioCryst Pharmaceuticals Earnings Conference Call
May 7, 2013
Q1 2013 BioCryst Pharmaceuticals Earnings Release (Tentative)
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -126.79% | -148.64% |
| Operating margin | -149.58% | -128.89% |
| EBITD margin | - | -119.81% |
| Return on average assets | -34.64% | -55.97% |
| Return on average equity | - | -544.61% |
| Employees | 40 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 200, 4505 Emperor Blvd
DURHAM, NC 27703
United States - Map
+1-919-8591302 (Phone)
+1-919-8591314 (Fax)
DURHAM, NC 27703
United States - Map
+1-919-8591302 (Phone)
+1-919-8591314 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza. The Company has two purine nucleoside phosphorylase (PNP) inhibitors that are in development, BCX4208 for the treatment of gout and forodesine for the treatment of hematological malignancies. The Company's pre-clinical compounds include BCX4161, an oral prophylactic drug for hereditary angioedema, and BCX5191, an adenine nucleoside analog targeting viral ribonucleic acid (RNA) polymerase for the treatment of hepatitis C.
Officers and directors
| Jon P Stonehouse | President, Chief Executive Officer, Director | |
| Thomas R Staab II | Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer | |
| William P. Sheridan | Senior Vice President, Chief Medical Officer | |
| Yarlagadda S. Babu Ph.D. | Vice President - Drug Discovery | |
| George B Abercrombie | Non-Executive Chairman of the Board | |
| Stanley C. Erck | Independent Director | |
| Nancy J. Hutson Ph.D. | Independent Director | |
| Peder K. Jensen M.D. | Independent Director | |
| Kenneth B Lee Jr. | Independent Director |